Amgen

Open: 224.44 Close: 224.06 Change: -0.38

Stop reading the whole internet to decide if you want to invest in Amgen.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Federal Trade Commission is seeking to block biopharmaceutical giant Amgen from acquiring Horizon Therapeutics. FTC filed a lawsuit in federal court to block the transaction. Deal was a bid to strengthen Amgens drug portfolio.

Today's News

U.S. sues to block amgens $27.8 billion takeover of horizon therapeutics - the new york times. Sanofi wins supreme court patent dispute with Amgen. FTC Sues to Block Amgens $27.8 Billion Acquisition of Horizon Therapeutics. Deal was a bid to strengthen Amgens drug portfolio as it prepares to face several patent expirations for key treatments. Federal Trade Commission is seeking to block biopharmaceutical giant Amgen from acquiring Horizon Therapeutics plc. FTC filed a lawsuit in federal court to block the transaction, saying it would enable Amgen to use rebates on existing blockbuster drugs. The U.S. Supreme Court issued its decision in Amgen, Inc. earlier today. Amgen agrees not to seek quick close to Horizon Therapeutics acquisition. Amgen agreed not to quickly close on its $27.8 billion acquisition. Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. FTC sues over Amgens $28-billion horizon therapeutics deal - Los Angeles Times Business. Federal Trade Commission (FTC) said Tuesday it will sue to stop Amgens $27.8B deal for Horizon Therapeutics. FTC Bureau of Competition Director Holly Vedova said: Rampant consolidation in the pharmaceutical industry has given powerful companies a pass Federal Trade Commission says deal would give Amgen unfair leverage to block competition for Horizon medications. Amgen said it was disappointed in the agencys decision. Amgen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. Amgen Dún Laoghaire consists of a 37,000 square metre aseptic manufacturing facility. Amgen is developing the capability to produce over 90% of its medicines in Dun Laoghaire, helping to ensure continuity of supply of our medicines as we expand internationally. Federal Trade Commission filed suit against Amgen in conjunction with Amgens recent $27.8 billion bid to acquire Horizon Therapeutics. FTC cited concerns that the acquisition would enable Amgen to use rebates on its existing blockbuster drugs to pressure insurance companies and pharmacy benefit managers.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, Horizon, Amgens, Therapeutics, say, block, and the most common words in the summary are: amgen, stock, horizon, best, news, ftc, market, . One of the sentences in the summary was: FTC filed a lawsuit in federal court to block the transaction. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #horizon #best #news #ftc #market.